Yanking Namenda IR Would Cost Medicare $6B, 2nd Circ. Told
As the Second Circuit weighs whether to uphold an injunction barring Actavis PLC from pulling an older, immediate-release version of Namenda from the market, the federal government has estimated without the...To view the full article, register now.
Already a subscriber? Click here to view full article